Last updated on September 2017

A randomized,double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib


Other Details:

For Study Locations, Click Here



Find a site near you

Start Over

Research Center

Loceted In: Additional Locations, MD USA
3.33miles
  Connect »

Research Center

Loceted In: Additional Locations, WA USA
3.33miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.